Acuta Capital Partners, LLC Relmada Therapeutics, Inc. Transaction History

Acuta Capital Partners, LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$18.3 - $37.02 $240,059 - $485,628	13,118 Added 3.72%	365,618 $13.5 Million
Q2 2022 Aug 15, 2022	BUY	$16.5 - $30.34 $173,250 - $318,570	10,500 Added 3.07%	352,500 $6.69 Million
Q1 2022 May 16, 2022	SELL	$16.72 - $26.99 $1.04 Million - $1.67 Million	-62,000 Reduced 15.35%	342,000 $9.23 Million
Q4 2021 Feb 14, 2022	BUY	$16.93 - $26.82 $6.84 Million - $10.8 Million	404,000 New	404,000 $9.1 Million
Q1 2021 May 17, 2021	SELL	$31.52 - $39.28 $3.78 Million - $4.71 Million	-120,000 Closed	0 $0
Q4 2020 Feb 16, 2021	SELL	$29.88 - $39.8 $4.69 Million - $6.25 Million	-157,000 Reduced 56.68%	120,000 $3.85 Million
Q3 2020 Nov 16, 2020	BUY	$34.42 - $43.78 $1.46 Million - $1.86 Million	42,500 Added 18.12%	277,000 $10.4 Million
Q2 2020 Aug 14, 2020	BUY	$31.59 - $49.98 $4.53 Million - $7.17 Million	143,550 Added 157.83%	234,500 $10.5 Million
Q1 2020 May 15, 2020	BUY	$23.78 - $50.12 $2.16 Million - $4.56 Million	90,950 New	90,950 $3.1 Million

12.3M

229K

138K

Ticker RLMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 28,608,500
Market Cap $10.9M
Description
Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that ...

Get notified when there are updates to the investment portfolio of Acuta Capital Partners, LLC, based on Form 13F filings with the SEC.

Stay updated on Acuta Capital Partners, LLC with notifications on news.